Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.002145%
Systemic lupus erythematosus23.03.02.006; 10.04.03.004; 15.06.02.003--Not Available
Tachycardia02.03.02.0070.001212%Not Available
Tachypnoea22.02.01.0140.000233%Not Available
Tendon disorder12.01.07.019; 15.07.01.0020.000140%Not Available
Tendonitis15.07.01.003; 12.01.07.0070.000326%Not Available
Tension19.06.02.005--Not Available
Tetany15.05.03.013; 14.04.01.005; 05.04.02.0030.000233%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000653%Not Available
Throat tightness22.12.03.031; 19.01.02.0050.000858%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000625%
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.002098%Not Available
Tooth disorder07.09.05.001--Not Available
Toothache07.09.06.0010.000140%
Torsade de pointes02.03.04.0050.000140%Not Available
Toxic encephalopathy17.13.01.004; 12.03.01.0270.000233%Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000513%
Tremor17.01.06.0020.001399%
Tricuspid valve incompetence02.07.05.0010.000513%Not Available
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Ureteric dilatation20.06.01.0070.000140%Not Available
Urinary retention20.02.02.0110.000559%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.0010.002145%
Uveitis10.02.01.023; 06.04.03.0030.000280%
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Vasculitis24.12.04.027; 10.02.02.0060.000186%
Vasospasm24.04.02.0020.000140%Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene